KR20010042373A - 핵 수용체 활성을 조절하는 방법 및 화합물 - Google Patents

핵 수용체 활성을 조절하는 방법 및 화합물 Download PDF

Info

Publication number
KR20010042373A
KR20010042373A KR1020007010940A KR20007010940A KR20010042373A KR 20010042373 A KR20010042373 A KR 20010042373A KR 1020007010940 A KR1020007010940 A KR 1020007010940A KR 20007010940 A KR20007010940 A KR 20007010940A KR 20010042373 A KR20010042373 A KR 20010042373A
Authority
KR
South Korea
Prior art keywords
receptor
nuclear
ligand
nuclear receptor
residues
Prior art date
Application number
KR1020007010940A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 시아우
피터 제이. 쿠쉬너
데이비드 에이. 아가드
제프리 엘. 그린
Original Assignee
린다 에스. 스티븐슨
더 리전트 오브 더 유니버시티 오브 캘리포니아
추후보정
에이알시에이치 디벨러프먼트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 린다 에스. 스티븐슨, 더 리전트 오브 더 유니버시티 오브 캘리포니아, 추후보정, 에이알시에이치 디벨러프먼트 코포레이션 filed Critical 린다 에스. 스티븐슨
Publication of KR20010042373A publication Critical patent/KR20010042373A/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020007010940A 1998-03-30 1999-03-30 핵 수용체 활성을 조절하는 방법 및 화합물 KR20010042373A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7995698P 1998-03-30 1998-03-30
US60/079,956 1998-03-30
US11314698P 1998-12-16 1998-12-16
US11301498P 1998-12-16 1998-12-16
US60/113,146 1998-12-16
US60/113,014 1998-12-16
PCT/US1999/006937 WO1999050658A2 (en) 1998-03-30 1999-03-30 Methods and compounds for modulating nuclear receptor activity

Publications (1)

Publication Number Publication Date
KR20010042373A true KR20010042373A (ko) 2001-05-25

Family

ID=27373576

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007010940A KR20010042373A (ko) 1998-03-30 1999-03-30 핵 수용체 활성을 조절하는 방법 및 화합물

Country Status (6)

Country Link
EP (1) EP1144997A3 (ja)
JP (1) JP2002516983A (ja)
KR (1) KR20010042373A (ja)
AU (1) AU3457199A (ja)
CA (1) CA2324060A1 (ja)
WO (1) WO1999050658A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060014A2 (en) * 1998-03-30 1999-11-25 The Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
AU2818200A (en) * 1999-03-01 2000-09-21 Karo Bio Ab Homology models of the glucocorticoid receptor
EP1222459A4 (en) * 1999-10-14 2003-01-22 Bristol Myers Squibb Co CRYSTALLOGRAPHIC STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN
FR2801311B1 (fr) * 1999-11-22 2005-08-26 Centre Nat Rech Scient Polypeptides derives du recepteur nucleaire de la vitamine d, et leurs utilisations notamment dans le cadre du criblage d'analogues de la vitamine d
CA2415103A1 (en) * 2000-06-30 2002-01-10 The Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
DE10036461A1 (de) * 2000-07-25 2002-02-07 Bayer Ag Ligandenbindedomäne des Ultraspiracle (USP)-Proteins
JP4593754B2 (ja) * 2000-10-13 2010-12-08 一般財団法人 化学物質評価研究機構 化学物質の５０％阻害濃度決定方法
JP2002296282A (ja) * 2001-04-02 2002-10-09 Enbiotec Laboratories:Kk 外因性内分泌攪乱物質の検出方法
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
GB0209507D0 (en) * 2002-04-25 2002-06-05 Karobio Ab Nuclear receptor structure
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
JPWO2005022436A1 (ja) * 2003-08-29 2006-10-26 独立行政法人産業技術総合研究所 蛋白質機能発現機構表示のための蛋白質構造三次元表示システム
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
WO2005040212A2 (en) * 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Orthogonal gene switches
CN102905685A (zh) * 2010-03-31 2013-01-30 株式会社爱茉莉太平洋 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
ES2097925T3 (es) * 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
EP0705279B1 (en) * 1993-05-27 2003-02-19 Selectide Corporation Topologically segregated, encoded solid phase libraries
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
CA2240024A1 (en) * 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains

Also Published As

Publication number Publication date
WO1999050658A3 (en) 2001-08-16
JP2002516983A (ja) 2002-06-11
EP1144997A3 (en) 2002-08-28
WO1999050658A2 (en) 1999-10-07
AU3457199A (en) 1999-10-18
EP1144997A2 (en) 2001-10-17
CA2324060A1 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
Wu et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism
KR20010042373A (ko) 핵 수용체 활성을 조절하는 방법 및 화합물
Fanning et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
Shiau et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
US20060149521A1 (en) Modulating nuclear receptor coactivator binding
Cutress et al. Structural basis for the nuclear import of the human androgen receptor
US6795776B1 (en) Crystallographic structure of the androgen receptor ligand binding domain
Pike et al. Structural insights into the mode of action of a pure antiestrogen
Wijayaratne et al. Comparative analyses of mechanistic differences among antiestrogens
Tiefenbach et al. SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription
Komolov et al. Structure of a GRK5-calmodulin complex reveals molecular mechanism of GRK activation and substrate targeting
Yu et al. Spatial definition of the human progesterone receptor-B transcriptional complex
US20050202440A1 (en) Inhibitors for androgen antagonist refractory prostate cancer
US8927297B2 (en) Methods to measure dissociation rates for ligands that form reversible covalent bonds
US20020072587A1 (en) Crystal structure of estrogen receptor-beta complex and uses thereof
Yudt et al. Preventing estrogen receptor action with dimer-interface peptides
US20040265809A1 (en) Polypeptides derived from retinoic acid-related orphan receptor(ror) and their applications
US7279325B2 (en) Method for identifying antagonist compounds of the estrogen-related receptor 3 (ERR3) by using the x-ray structural coordinates of the ligand binding domain
EP1265927B1 (en) Crystal
US8187871B2 (en) Co-crystallization of ERR-α with a ligand that forms a reversible covalent bond
Berry Regulation of estrogen receptor-alpha ubiquitination and proteasome-mediated receptor degradation
Kushnert et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen
Yi Studies on mechanisms of estrogen receptor subtype-specific transcription regulation
Greene Structural Determination of Certain Novel ER Complexes
Wu et al. Structural Determination of Certain Novel ER Complexes

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application